NA
OBIO icon

NewEdge Advisors’s Orchestra BioMed OBIO Stock Holding History

NewEdge Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$187K Hold
44,083
– – ﹤0.01% 2611
2025
Q4 		$183K Hold
44,083
– – ﹤0.01% 2604
2025
Q3 		$109K Hold
44,083
– – ﹤0.01% 2578
2025
Q2 		$118K Buy
+44,083
New +$129K ﹤0.01% 2367

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

NewEdge Advisors's OBIO Position: Q1 2026 in Review

NewEdge Advisors held its Orchestra BioMed (OBIO) position steady in Q1 2026 at 44,083 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

NewEdge Advisors first reported a position in OBIO in Q2 2025 and has held it in 4 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • NewEdge Advisors held 44,083 shares of Orchestra BioMed worth $187K as of Q1 2026.
  • NewEdge Advisors left its Orchestra BioMed share count unchanged in Q1 2026.
  • Orchestra BioMed made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2611 holding.
  • NewEdge Advisors first reported a position in Orchestra BioMed in Q2 2025 and has held it in 4 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.